SCHEMBL3154164

SCHEMBL3154164

Cc1ccnc(CC2CCCN2C(=O)c2ccc(S(=O)(=O)Nc3nccs3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.51
SCN8A Q9UQD0 2/20 0.51
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 3/20 0.45
TSHR P16473 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44
PKM P14618 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
STAT3 P40763 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PTPN1 P18031 1/20 0.42
DUSP3 P51452 1/20 0.42
PTPN11 Q06124 1/20 0.42
PTPN22 Q9Y2R2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3162923 0.87 SCN9A (0.49) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3166856 0.85 SCN9A (0.53) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3168619 0.84 SCN9A (0.52) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3169013 0.84 SCN9A (0.59) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3169729 0.82 PKM (0.58) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3169958 0.81 SCN9A (0.63) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL4172971 0.81 TRPC3 (0.44) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3169619 0.81 SCN9A (0.54) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3167052 0.81 SCN1A (0.54) SCN9ASCN8AMEN1KMT2AALDH1A1
SCHEMBL3171643 0.81 SCN9A (0.54) SCN9ASCN8AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN9A 51/4885SCN8A 75/4885MEN1 4729/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN9A 51/4885SCN8A 75/4885MEN1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.